Plain-English translation of NCT06188650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new way to treat advanced non-small cell lung cancer in patients whose cancer has continued to grow despite two previous rounds of treatment. The approach combines three components: a minimally invasive procedure called DEB-BACE (which delivers chemotherapy directly to the tumor's blood supply), along with two medications called and adebelimumab. Researchers want to see if this combination approach can help shrink tumors and improve how long patients survive.
When lung cancer becomes advanced and stops responding to standard treatments, patients have very limited options. This trial exists to explore whether combining a targeted delivery procedure with two newer medications might offer a better chance of controlling the cancer in people who have already tried two other treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the minimally invasive procedure (DEB-BACE), rest for about a week, and then begin taking the two medications as part of one treatment cycle. Depending on how well the treatment is working, you may receive up to four procedures total, followed by continued treatment with the medications. The trial will monitor how your cancer responds and track any side effects throughout your participation.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China